INTRODUCTION 47 4 (accession no. NP_001119580.1), in which exon 20 is nine amino acids shorter than in 78 NCC 1 . Following studies confirmed the presence of both long and short form of the exon 79 20 (20a and 20b respectively) as a result of a possible cryptic splicing donor site (22) . 80
Moreover, cDNA analysis indicated that NCC 3 constitutes the predominant form in the 81 human kidney (22) . Isoform 2 (NCC 2 ) (accession no. NP_001119579.1) is only one amino 82 acid shorter than NCC 1 . Recently, Gonzales et al.(15) used a proteomic approach to 83 analyze human urinary exosomes and identified a novel phosphorylation site at serine 84 (Ser811). This residue is present only in NCC 1 and NCC 2 . Interestingly, mouse and rat 85 SLC12A3 genes do not contain the segment coded by human exon 20, hence NCC 1 and 86 NCC 2 are not present in these animals. The lack of NCC 1 and NCC 2 in rodents hampered 87 the progress and interest towards further investigations and until now NCC 3 has 88 predominantly been studied (8, 12) . At present, detailed localization of NCC 1 and NCC 2 89 proteins in human kidney, their regulatory network, and relevance in renal Na + handling 90 remain to be elucidated. 91
92
The goal of the present study was, therefore, to determine the abundance and localization 93 of previously underrepresented NCC isoforms in comparison to NCC 3 in the human kidney 94 as well as their functional properties and regulation in physiological conditions. To this end, 95 the presence of NCC 1 , NCC 2 , and NCC 3 in the human urinary exosomes was assessed by 96 mass spectrometric analysis. The localization and regulation of NCC isoforms was 97 investigated by immunohistochemical analysis in human kidney biopsies and by 98 immunoblotting of kidney membrane fractions and urinary exosomes with newly developed 99 isoform specific antibodies. Functional capacity to transport Na + by NCC 1 was determined 100 using the Xenopus oocytes expression system. Furthermore, to evaluate physiological 101 regulation of NCC isoforms during acute water loading of human subjects was chosen as a 102 model, since hormones maintaining water balance are known to regulate NCC (5, 28, 30-34, 41, 42) . 104 105
MATERIALS AND METHODS 106
Isolation and sequencing of NCC variants from human kidney 107 Human kidney cDNA was amplified using primers against the C-terminal domain of NCC. 108
The PCR product was isolated, cloned into the pGEM®-T Easy Vector System (Promega), 109 and transformed into DH5-E. Coli bacteria. Colonies were isolated, plasmid DNA was 110 extracted, and submitted for Sanger sequencing. The resulting chromatograms from the 111 sequencing confirmed the presence of NCC 1/2 and NCC 3 in the human kidney. 112
113
Real-time relative All 7 donors gave permission for donating their kidneys after death. In case the kidney 115 appeared not suitable for transplantation the donor gave permission to use the kidneys for 116 research purposes, which is registered in the Dutch Donor registry. Relative amount of 117 NCC 1/2 and NCC 1-3 mRNA in the human kidney was determined by a real-time based on the standard curve method (46) . RNA from 7 healthy humans kidney cortex was 119 isolated with Trizol Reagent (Life Technologies, Grand Island, NY, USA) and cDNA was 120 synthesized with moloney murine leukemia virus (M-MLV) revers transcriptase (Invitrogen, 121 Grand Island, NY, USA). Following primers amplifying specifically NCC 1/2 as well as 122 primers against N-terminal fragment recognizing both NCC 1/2 and NCC 3 combined (NCC 1-123 3 )
were used: NCC 1/2 Fw: GTGCCAGGCCATCAGTCT; NCC 1/2 Rev: 124 TATGGTCTTCTTGCCCTGCT; NCC 1-3 Fw: TGTTTGGGGCTATCATCTCC; NCC 1-3 Rev: 125 GAGGAGCCCCAATTTACCTC. Standard curve was prepared based on mixed DNA 126 plasmids containing both NCC 1/2 and NCC 3 dilutions ranging from 2.5 × 10 5 -5.12 × 10 8 . 127
Quantification was performed with iQ SYBR Green supermix system (Bio-Rad, Hercules, 6 CA, USA) according to manufacturer's instructions. The products of the RT-PCR were 129 verified by sequencing. The absolute copy number per µg of mRNA isolated form the 130 human cortex was defined and the ratio of NCC 1/2 to NCC 1-3 was determined. 131 132
Mutagenesis and constructs 133
Human NCC in pT7Ts has been previously described. (7) The human NCC 1 fragment was 134 generated by site directed mutagenesis using the QuikChange site-directed mutagenesis 135 kit (Stratagene, La Jolla, CA, USA) with the following primers: Fw 136
GCGCCAGAGGTGCCAGGCCATCAGTCTCTGGCGCTTTGGACCCCAAGGC;
Rev: 137 GCCTTGGGGTCCAAAGCGCCAGAGACTGATGGCCTGGCACCTCTGGCGC;
and 138 subsequently inserted in the NCC 3 -pT7Ts. The NCC 1 phosphomutants mimicking the 139 active (S811D) and the inactive (S811A) phosphorylation sites were generated by site 140 directed mutagenesis. Primers: S811D Fw: GTGCCAGGCCAGACGTCTCTGGCGCTTTG; 141 Rev:
CAAAGCGCCAGAGACGTCTGGCCTGGCAC; S811A Fw: 142
GTGCCAGGCCAGCAGTCTCTGGCGCTTTG;
Rev: 143 CAAAGCGCCAGAGACTGCTGGCCTGGCAC. eGFP-NCC in pT7Ts was described 144 previously. (7) The C-terminal part of human NCC 1 in pT7Ts was subcloned into the eGFP-145 NCC construct. For expression in mammalian systems, human eGFP-NCC 3 fragment 146 described previously (7) was subcloned into empty pCMV-SPORT6 vector. Human NCC 1 147 and NCC 1 phosphorylation site mutants (S811A and S811D) fragments were subcloned to 148 eGFP-NCC 3 pCMV SPORT6 construct. All the constructs were confirmed by sequence 149 analyses. 150
151
In vitro cRNA translation for functional assays 152
Microinjection of cRNA and 22 Na + uptake experiments were performed essentially as 153 described previously (7) . Briefly, constructs encoding the NCC variants were linearized, 154 7 transcribed in vitro using the mMESSAGE mMACHINE ® T7 Kit (Ambion, Austin, TX, USA). 155
The integrity of the product was confirmed on 1% w/v agarose, 37% v/v formaldehyde gels 156 and cRNA aliquots were stored at -80°C. 157
158
Oocyte harvesting and animal experimentation 159
All animal experiments received the approval from the animal ethics board of Radboud 160 university medical center, Nijmegen, The Netherlands. Xenopus laevis oocytes were 161 processed based on previous established protocols (7). Mature oocytes were selected and 162 microinjected with 5 ng of cRNA encoding the human NCC 1 , NCC 3 , NCC 1 S811D, NCC 1 163 S811A or co-injected with 10 ng of WNK4 cRNA. 22 Na + uptake was corrected for the 164 surface expression of the corresponding microinjected variant and expressed as a percent 165 of WT uptake. All the experiments using 22 Na + radioisotope were approved and monitored 166 by the Environmental Health and Radiation Safety office, Radboud university medical 167 center. 168
169

Quantification of eGFP-NCC in the oocyte membrane 170
Surface expression analyses were performed as described in detail previously (7) . Briefly, 171 oocytes were microinjected with 5 ng of cRNA encoding eGFP-NCC 1 , eGFP-NCC 3 , or 172 eGFP-NCC 1 phosphorylation site mutants. All images were acquired on an Olympus 173 FV1000 laser-scanning microscope (Center Valley, PA, USA) using a 10 x water objective. 174 Densitometry analysis of fluorescence was done using Image J software (image 175 processing program, NIH, Bethesda, MA, USA). Autofluorescence of water-injected 176 oocytes was subtracted from the fluorescence of all injected variants. 177
178
Cell culture, transfection, and isolation of enriched plasma membrane HEK293 cells were cultured on 100 mm dishes and grown in DMEM supplemented with 180 10% v/v fetal bovine serum, nonessential amino acids, and 2 mM L-glutamine. Cells were 181 transfected with eGFP-NCC 3 pCMV SPORT6, eGFP-NCC 1 pCMV SPORT6, eGFP-NCC 1 182 S811D pCMV SPORT6 and eGFP-NCC 1 S811A pCMV SPORT6 vector using 32 μg of 183 DNA and 96 μl of polyethylenimine (Polysciences, Inc., Warrington, PA, USA). Cells 184 transfected with empty vector were used as controls (mock). At 48 hours post-transfection 185 the cells were lysed in 1 ml of ice-cold dissection buffer per dish (300 mM sucrose, 25 mM 186 imidazole, 1 mM EDTA, 1 μg/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 187 μg/ml leupeptin and 5 μg/ml apropotin). Lysed cells were centrifuged at 4,000 x g for 8 188 minutes and subsequently the supernatant was centrifuged at 16,000 x g for 40 minutes. 189
The pellet was resuspended in ice-cold dissection buffer and 1x Laemmli (0.4% w/v SDS, 190 2% v/v glycerol, 12 mM Tris-HCl pH 6.8, 40 mM DTT and 0.002% w/v bromophenol blue) 191 was added. Samples were incubated in 65°C for 15 minutes. BCA Protein Assay Kit 192 (Pierce, Thermo Scientific, Rockford, IL, USA) was used to determine the protein 193 concentration. 194
195
Kidney membrane preparations for NCC immunoblots 196
All three donors gave permission for donating their kidneys after death. In case the kidney 197 appeared not suitable for transplantation the donor gave permission to use the kidneys for 198 research purposes, which is registered in the Dutch Donor registry. Harvested kidneys 199 were snap-frozen immediately after isolation and homogenized in detergent-free lysis 200 buffer containing 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM sodium 201 orthovanadate, 5 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 202 0.1% v/v 2-mercaptoethanol and protease inhibitors (Roche, 1 tablet per 50 ml) with a 203 homogenizer (VWR VDI 12 Adaptable Homogenizers, OpticsPlanet, Inc., Commercial 204 Avenue Northbrook, IL, USA). Nuclei and debris were pelleted by centrifugation at 1,500 x 205 g for 5 minutes at 4°C. Next, supernatants were centrifuged at 100,000 x g for 1 hour at 206 4°C. The pellet was washed with 1 vol. of lysis buffer without reducing agent and 207 centrifuged again at 100,000 x g for 15 minutes to remove any remaining cytosolic 208 particles. The pellet was then resuspended in lysis buffer including 1% v/v Nonidet P40. 209 BCA Protein Assay Kit (Pierce, Thermo Scientific, Rockford, IL, USA) was used to 210 determine the protein concentration. Finally, samples were stored at -80°C for the 211 immunoblotting. Anti NCC 1/2 rabbit polyclonal antibody was manufactured by 21 st Century Biochemicals 237 (Marlborough, MA, USA). Briefly, peptide corresponding to the sequence NH 2 -238 ARGARPSVSGALDP-COOH was manufactured by Fmoc chemistry and after 239 cleavage/deprotection was HPLC purified to >90%, and the mass and sequence verified 240 by nanospray MS and CID MS/MS, respectively. This peptide was conjugated to carrier 241 protein and used to immunize two New Zealand rabbits. After multiple boosts and bleeds, 242 the serum was immunodepleted by affinity purification of the antibody specific to NCC 1/2 243 with affinity column containing the immunizing peptide. The antibody was used at the 244 following dilution rates: IB 1:1,000, IHC 1:50. Rabbit polyclonal antibody against the N-245 terminal portion of rat NCC (Millipore, Billerica, MA, USA, #AB3553; IB 1:2,000, IHC 1:50). 246
Rabbit polyclonal antibody against rat (R7) AQP2 (kindly provided by Dr. Peter Deen; IB 247 1:3,000).(6) Mouse monoclonal antibody against amino acids 101-210 of CD9 of human 248 origin (C4, Santa Cruz Biotechnology, Inc., CA, USA; IB 1:500). Secondary antibodies 249 were as follows: peroxidase conjugated goat anti-rabbit (Sigma-Aldrich, St. Luis, MO, 250 USA, #A4914; IB 1:10,000), goat anti-rabbit Alexa Fluor® 488 (Molecular Probes, Eugene, 251 OR, USA, #A-11029, IHC 1:300). 252
253
Acute water loading 254
The study was conducted according to the principles expressed in the declaration of 255
Helsinki. All participants gave written informed consent and the study protocol was approved by the Institutional Review Board of the Radboud university medical center, 257
Nijmegen, The Netherlands (approval number NL47178.091.13). Healthy males between 258 25 to 35 years old and with a body weight below 100 kg body weight were included in the 259 study. Subjects were asked to refrain from coffee, tea, alcohol intake and any vigorous 260 exercise for 24 hours before and during the study. Subjects did not drink or eat for 12 261 hours before the first urine collection to achieve maximal urine concentration. Each subject 262 ingested 20 ml/kg body weight of water in 30 minutes. Midstream urine was collected 263 before (time 0 minutes) and after water ingestion in 30 minutes intervals up to 150 264 minutes. Collected urine samples were supplemented with a final concentrations of 265 protease inhibitors of 50 µM phenylmethylsulfonyl (PMSF), 20 µM aprotinin, 10 µM 266 pepstatin A, 20 µM leupeptin, and stored at -80°C. 267
268
Urinary exosome isolation 269
The urine samples were collected from healthy subjects after acute water loading (see 270 Supplement). Ten ml of collected urine was centrifuged at 17,000 × g for 15 minutes at 271 24°C in ultracentrifuge (Sorvall™ WX Floor Ultra Centrifuges, Thermo Scientific, Asheville, 272 NC, USA) with 70.1Ti rotor. Supernatant was stored at room temperature for 25 minutes. 273
The pellet was resuspended in 200 μl isolation solution (250 mM sucrose and 10 mM 274 triethanolamine-HCl, pH 7.6) and 50 μl 3.24 M dithiothreitol (DTT), subsequently 275 centrifuged at 17,000 × g for 15 minutes at 24°C. Thereafter, the supernatant was 276 collected, combined with supernatant obtained from the previous step and centrifuged at 277 200,000 × g for 2 hours at 24°C. Exosome pellet was dissolved in 50 µl of 1.5 × Laemmli 278 (0.6% w/v SDS, 3% v/v glycerol, 18 mM Tris-HCl pH 6.8 and 0.003% w/v bromophenol 279 blue). All the samples were stored in -20°C for further use. 280
Mass spectrometry 282
Gel slices were cut from the Coomassie-stained and washed SDS PAGE gel on a clean 283 glass plate and were further diced in 1 mm 3 cubes using a scalpel and were transferred to 284 a 1.5 ml reaction tube for further processing. ¼ gelband equivalent was processed for 285 trypsin digestion and ¾ gelband was processed for Lys-C digestion. Gel cubes were 286 vortexed in 400 µl 50 mM NH 4 HCO 3 for 10 minutes. Supernatant was removed and the gel 287 cubes were vortexed in 400 µl 50 mM NH 4 HCO 3 , 50% v/v acetonitrile for 10 minutes. After 288 removal of the supernatant this wash-step was repeated once. Gel cubes were reduced in 289 10 mM DTT in 50 mM NH 4 HCO 3 at 56°C in a heating block for 60 minutes. After cooling 290 down the supernatant was removed and gel cubes were alkylated with 54 mM 291 iodoacetamide in 50 mM NH 4 HCO 3 for 45 minutes in the dark at RT. Supernatant was 292 removed and gel cubes were vortexed in 400 µl 50 mM NH 4 HCO 3 for 10 minutes. 293
Supernatant was removed and the gel cubes were vortexed in 50 mM NH 4 HCO 3 /50% v/v 294 acetonitrile. After removal of the supernatant this wash-step was repeated once. 295
Supernatant was removed and gel cubes were dried in a vacuum centrifuge at 50°C for 10 296 minutes. Dried gel slices were covered with trypsin solution or Lys-C solution (6.25 ng/µl in 297 50 mM NH 4 HCO 3 ), after rehydration of the cubes excess protease was removed and gel 298 cubes were covered with 50 mM NH 4 HCO 3 . Digestion proceeded overnight at 25°C in a 299 heating block. After digestion, peptides were extracted from the gel cubes with 100 µl 1% 300 v/v formic acid by vortexing. Supernatant was transferred to a 1.5 ml tube and gel cubes 301 were extracted with 100 µl 5% v/v formic acid 50% v/v acetonitrile. Supernatant was 302 pooled with the first eluate. The second extraction was repeated once and the supernatant 303 was pooled with previous extracts. Extracts were concentrated in a vacuum centrifuge at 304 50°C and volumes were adjusted to 50 µl by adding 0.05% v/v formic acid. 305
306
LC-MS/MS
Packings, Amsterdam, The Netherlands) equipped with a 20 cm × 75 μm ID fused silica 309 column custom packed with 1.9 μm 120 Å ReproSil Pur C18 aqua (Dr Maisch GMBH, 310 Ammerbuch-Entringen, Germany). After injection (15/50 µl Lys-C digest; 20/50 µl trypsin 311 digest), peptides were trapped at 6 μl/minute on a 10 mm × 100 μm ID trap column packed 312 with 5 μm 120 Å ReproSil Pur C18 aqua at 2% buffer B (buffer A: 0.5% v/v acetic acid in 313 MQ; buffer B: 80% v/v ACN + 0.5% v/v acetic acid in MQ) and separated at 300 nl/minute 314 in a 10-40% buffer B gradient in 60 minutes (90 minutes inject-to-inject) at 50˚C. Eluting 315 peptides were ionized at a potential of +2 kVa into a Q Exactive mass spectrometer 316 (Thermo Fisher, Bremen, Germany). Intact masses were measured at resolution 70.000 317 (at m/z 200) in the orbitrap using an AGC target value of 3 × 10 6 charges. The top 10 318 peptides signals (charge-states 2 + and higher) were submitted to MS/MS in the HCD 319 (higher-energy collision) cell (1.6 amu isolation width, 25% normalized collision energy). NCC 1 and NCC 2 . NCC 1 contains one extra amino acid as compared to NCC 2 , which is 360 localized outside the exon 20 region. Therefore, NCC 1/2 will refer to the combined 361 presence of NCC 1 and NCC 2 , as these are indistinguishable in several of the experimental 362 assays performed in this study. The NCC 1/2 is present and preserved between some 363 mammalian species (human and rabbit), but is not present in rodents (mouse and rat). In 364 humans, the NCC splice site is encoded by exon 20 (Fig. 1B) . Remarkably, this exon is 365 absent in mouse and rat due to the lack of splice sites. Fig. 1B shows the exon 366 prearrangement of NCC 1/2 . Sequence analysis of cDNA fragments isolated from human 367 kidney showed that both NCC 1/2 and NCC 3 are present (Fig. 1C ). NCC 1/2 is longer than 368 NCC 3 due to the presence of nine extra amino acid residues in the C-terminal domain (Fig.  369   1D) . The phosphorylation site identified in the additional fragment corresponds to residue 370 S811 (Fig. 1D ). Constructs encoding NCC 3 and NCC 1 as well as the phosphorylation site 371 mutants (S811D and S811A) ( Fig. 1D) Table 2 all identified SLC12A3 peptides are summarized. Two regions in the amino-acid sequence allow distinction between the 384 isoforms: Peptides correlated to V807L and 9 amino-acid deletion peptides indicating the 385 presence of both NCC 3 as well as NCC 1/2 were identified. Isoform-specific peptides 386 spanning residues 781-838 are shown in Table 3 . Specifically, Lys-C digestion yields 387 MMQAHINPVFDPAEDGKEASARGARPSVSGALDPK (NCC 1/2 res 785-820, Andromeda 388 score 49.2) and MMQAHINPVFDPAEDGKEASARVDPK (NCC 3 res 785-811, Andromeda 389 score 70.3), as well as EASARGARPSVSGALDPK (NCC 1/2 res 802-820, Andromeda 390 score 57.5) and EASARVDPKALVK (NCC 3 res 802-815, Andromeda score 32.9). Tryptic 391 digestion additionally yielded GARPSVSGALDPK (NCC 1/2 res 807-820, Andromeda score 392 122.5) and PSVSGALDPK (NCC 1/2 res 810-820, Andromeda score 104.8). Identification of 393 multiple overlapping peptides of both NCC 3 as well as NCC 1/2 firmly indicated that in 394 exosomes, the SCL12A3 gene product is present as a mixture of NCC 3 and at least one 395 and possibly both NCC 1 and NCC 2 . 396 397 Generation of specific antibodies against NCC 1/2 398 NCC 1/2 -specific peptide epitope (ARGARPSVSGALDP) was used to generate anti-NCC 1/2 399 antibodies. Specificity of the antibody was tested using isolated membranes from HEK293 400 cells transfected with corresponding plasmids. A commercially available antibody against 401 the N-terminal portion of NCC detected NCC 3 as well as NCC 1/2 , as all are carrying the 402 recognized epitope ( Fig. 2A) . Therefore, in the present study expression of NCC, detected 403 by the antibody against the N-terminal NCC, refers to the combined expression of NCC 3 404 and NCC 1/2 hence denoted as NCC 1-3 . The antibody specific for NCC 1/2 recognized only 405 NCC 1/2 , but not NCC 3 and NCC 1/2 mutants (S811A and S811D) (Fig. 2B ). This 406 demonstrates the high specificity of the newly generated antibody against the NCC 1/2 407 epitope. Immunoreactivity was not present in cells transfected with mock vector or in the 408 presence of specific blocking peptides (Fig. 2C) .
410
Immunoblot identification of human NCC isoforms 411
Immunoblots of kidney membrane fractions and urinary exosomes of three subjects 412 showed two immunopositive protein bands of approximately 260 and 130 kDa, 413
representing the dimeric and monomeric form of the NCC 1-3 transporter, respectively (Fig.  414   2D) . Importantly, the NCC 1/2 protein was also detected in kidney membrane fractions and 415 urinary exosomes as two bands of approximately 260 and 130 kDa as evidence for the 416 dimeric and monomeric form, respectively ( Fig. 2E ). This indicates that NCC isoforms are 417 present in oligomeric structures in the human kidney and urinary exosomes. 418
NCC 1/2 localizes to apical membrane of DCT 420
Immunohistochemical staining of human kidney serial sections revealed expression of 421 NCC 1-3 ( Fig. 3A and B ) and NCC 1/2 ( Fig. 3C and D) at the apical membrane of epithelial 422 cells lining the DCT. Expression of both NCC 1-3 and NCC 1/2 was restricted to the same 423 tubular sites. 424 425
Functional characterization of NCC 1 426
In order to compare the functional abilities of NCC 1 and NCC 3 , cRNA of the respective 427 variants was microinjected into Xenopus laevis oocytes and thiazide-sensitive 22 Na + 428 uptake was measured (Fig. 4) . It has been shown previously that cumulative amounts of 429 eGFP-NCC correlate dose-dependently with the eGFP-NCC fluorescence at the oocyte 430 membrane and with thiazide-sensitive 22 Na + uptake (7). For the analysis, day 4 after cRNA 431 injection was chosen. Thiazide-sensitive 22 Na + transport was significantly increased in the 432 NCC 1 compared to the NCC 3 (Fig. 4A ). To further evaluate whether this increase in 433 transport was dependent on the phosphorylation at S811 the effect of substituting the serine residue by an aspartic acid to mimic constitutive phosphorylation was tested. The 435 S811D mutant exhibited a significant increase in thiazide-sensitive 22 Na + uptake in 436 comparison to NCC 3 and NCC 1 . Moreover, the S811A mutant mimicking a constitutively 437 inactive phosphorylation site showed a significant decrease in thiazide-sensitive 22 Na + 438 uptake, as compared to NCC 1 S811D variants (Fig. 4A) . 439 440 WNK4 has previously been shown to reduce forward trafficking of NCC in the oocyte 441 system, by diverting the cotransporter to the lysosomal compartment (38, 49) . Additionally, 442 WNK 4 modulates SPAK/OSR1 phosphorylation and hence NCC activity (4, 43). To 443 elucidate whether WNK4 has similar effects on NCC 1 , cRNA encoding the NCC variants 444 were co-injected with WNK4. WNK4 reduced NCC-dependent 22 Na + uptake to similar 445 levels in all conditions, suggesting that the majority of NCC 1 activity is sensitive to WNK4 446 inhibition in S811 independent manner (Fig. 4A) . In each condition 22 Na + uptake was 447 thiazide-sensitive (Fig. 4A, black bars) . To determine surface expression of injected cRNA, 448 fluorescent intensity of eGFP-tagged NCC 3 , NCC 1 , NCC 1 S811D or NCC 1 S811A was 449 quantified ( Fig. 4B and C) . 450 451 Acute water loading 452 Acute water loading was performed in six healthy subjects to determine the effect of 453 hypervolemia on the renal expression of NCC isoforms. Urine was collected before (time 454 0) and after acute water loading in 30-minute intervals up to 150 minutes. Urinary 455 exosomes of each subject were loaded according to the urine creatinine concentration 456 onto the gel and to confirm equal loading of the samples, the abundance of the exosomal 457 marker CD9 was determined (1, 11) . Our study demonstrated the existence of NCC in 458 dimeric and monomeric forms in urinary exosomes using immunoblotting. Therefore, both 459 dimeric and monomeric forms were analyzed separately. Immunoblots probed for NCC 1/2 showed a significant decrease of NCC 1/2 monomer and dimer expression 60 minutes after 461 acute water loading, which returned to the baseline levels at 150 minutes (Fig. 5A, C and 462 E). Expression of NCC 1-3 monomer and dimer significantly dropped 60 minutes after acute 463 water loading and restored after 150 minutes (Fig. 5B, D and F) . The exosomes were also 464 probed for the expression of aquaporin 2 (AQP2) since water loading is known to 465 downregulate AQP2 (36). Indeed, AQP2 expression in urinary exosomes was significantly 466 reduced 60 minutes after acute water loading ( Fig. 6A and B ). CD9 expression levels 467 within urinary exosomes did not change significantly at different time points, suggesting 468 equal loading of exosomes ( Fig. 5G, 5H , 6C, respectively). Urine osmolality decreased 469 significantly 30 minutes after acute water loading (Fig. 6D) . 470
471
DISCUSSION 472
Since 1996, when human NCC was cloned, it has been shown that three isoforms of NCC 473 are present in the human kidney (22, 23, 35) . However, all NCC studies have focused on 474 the shorter isoform, NCC 3 , leaving the alternative splice variants unexplored. In the 475 presented study, we delineated for the first time the localization, abundance, and 476 functionality of NCC 1/2 in the human kidney by showing that: i) mRNA of NCC 1/2 constitutes 477 approximately 44% of all NCC (NCC 1-3 ) transcripts in the human kidney; ii) NCC 1/2 is 478 clearly detectable in human urinary exosomes by mass spectrometry and immunoblot 479 analysis; iii) NCC 1/2 is, like the shorter NCC 3 isoform, present at the apical membrane of 480 DCT; iv) phosphorylation at S811 regulates NCC 1 function; v) the abundance of NCC 1/2 is 481 regulated in response to physiological stimuli such as acute water loading. 482 483 Generation of new antibodies specifically recognizing NCC 1/2 allowed us to demonstrate 484 the presence of NCC 1/2 at the apical membrane of the DCT, present in the human kidney as well as monomeric and dimeric complexes in kidney membrane fractions and urinary 486 exosomes. The presence of NCC 1/2 in the exosomes was confirmed by mass 487 spectrometry. Noteworthy, all antibodies raised against NCC 3 recognize also NCC 1/2 . 488 Thus, in previously performed studies on endogenous human NCC also NCC 1/2 may have 489 been detected. Because human NCC 1 and NCC 2 differ only by one amino acid it was 490 impossible to differentiate between both isoforms with the immunodetection methods. 491
Therefore, it was addressed as a combined expression of both isoforms, NCC 1/2 . We 492 demonstrated that NCC 1/2 mRNA constitutes a substantial amount (44%) of total NCC 493 mRNA in the human kidney. Nevertheless, the relative protein abundance of each isoform 494 depends on the translation and quality control of the proteins. Therefore, the expression 495 level of mRNA does not always mirror the abundance of the protein. Moreover, presented 496 mRNA analysis characterizes a combined expression of NCC 1 and NCC 2 since they were 497 indistinguishable. Hence, the ratio of each isoform is not strictly determined. 498 499 Functional characterization of NCC 1 and the role of its phosphorylation site S811 were 500 investigated by using Xenopus oocytes. As NCC 3 , NCC 1 demonstrated thiazide-sensitive 501 22 Na + transport. Additionally, NCC 1 activity can also be modified by changes in 502 phosphorylation status. Splicing and subsequent single point directed mutagenesis to 503 mimic constitutively active phosphorylation sites of NCC 1 (S811D) led to an increased 504 activity of NCC 1 compared to NCC 3 . We demonstrated that once the S811 residue is 505 substituted by an alanine (S811A) mimicking inactive site, the activity of the splice variant 506 is significantly decreased. The fact that inhibition of S811 phosphorylation reverts 507 transporter capability only to basal levels implies that the NCC 1/2 and its phosphorylation is 508 introduced in order to augment transport of NCC over the baseline level when needed. Our 509 functional experiments demonstrated that WNK4 is a strong inhibitor of both NCC 1 and 510 NCC 3 . However, the effect of WNK4 is not mediated via S811 phosphorylation, since the constitutively active S811D mutant is not protected from the inhibitory effects of WNK4. 512 This suggests that in both isoforms, NCC 1 and NCC 3 , the effect of WNK4 is mediated via 513 regulation at the N-terminus. Additionally, phosphorylation at S811 may depend on 514 simultaneous regulation of the phosphorylation at the N-terminal residues. 515 516 In order to determine NCC 1/2 expression in vivo, human urinary exosomes were analyzed. 517
Exosomes are frequently used as biomarkers for renal tubular disorders as they reflect 518 changes in the expression of different proteins present in the tubular epithelial cells (16, 519 40) . For instance, it has been demonstrated that patients with Gitelman syndrome do not 520 express NCC in their urinary exosomes (19) . In contrast, patients with familial 521 hyperkalemic hypertension characterized by enhanced activity of NCC, have increased 522 NCC expression in their urinary exosomes (17, 24) . This substantiates the notion that NCC 523 abundance in urinary exosomes reflects the actual state of NCC expression in the DCT as 524 postulated previously (16, 40) . We hypothesized that the activity of NCC 1/2 can be modified 525 by changes in the protein abundance at the plasma membrane. Depending on a stimulus 526 (hormones, electrolyte concentration, etc.) NCC expression throughout the DCT can be 527 altered by the insertion of a more potent isoform (NCC 1/2 ) into the apical membrane, in 528 order to maximize NaCl transport and vice versa. Consequently, we showed that NCC 1/2 529 and NCC 1-3 abundance in urinary exosomes is robustly down regulated in response to 530 water loading (Fig. 5) . Increased activity and expression of NCC in response to changes in 531 the renin-angiotensin-aldosterone system and vasopressin has been well documented (5, 532 28, 30-34, 41, 42) . Hence, decreased NCC abundance at the apical plasma membrane in 533 water-loaded subjects is likely a result of hypervolemia, hyponatremia, and a subsequent 534 decline in vasopressin release. 535
Thus far, signaling pathways regulating NCC 1/2 are unknown. However, prediction software 537 (pkaPS) from the IMP-IMBA Bioinformatics group (26) suggested that the phosphorylated 538 sequence around S811 of NCC 1/2 shows high similarity to a PKA consensus site. 539 Therefore, potential hormones regulating the cAMP-PKA pathway might be involved in 540 regulating transport via this kinase. Several hormonal systems have been shown to 541 activate the cAMP-PKA pathway in the DCT (3, 9) . Our water loading study substantiates 542 the regulatory effect of vasopressin not only on NCC 1-3 but also specifically on NCC 1/2 543 abundance in the kidney. Since S811 may contain PKA consensus site we hypothesized 544 that a PKA-dependent mechanism could be occurring for the phosphorylation at S811 in 545 response to vasopressin stimulation. Nevertheless, recent studies demonstrated a 546 potential role for vasopressin in modulating NCC N-terminal phosphorylation in the DCT 547 (25, 28, 34) , which may constitute the main regulatory mechanism for all NCC isoforms 548 since all variants contain the same N-terminal phosphorylation sites. 549 550 Our data clearly demonstrates that NCC 1/2 is not a redundant transcription product, but it 551 merely constitutes a fully functional thiazide-sensitive NaCl-transporting protein. In parallel, 552
we propose a novel way of NCC regulation by phosphorylation at the C-terminal S811 553 residue that adds to the complex system governing the regulation of NCC. Future 554 experiments developing S811 phospho-specific antibodies and samples from different 555 human pathological states could aid in determining the precise regulation of NCC 1/2 . A 556 better understanding of the regulation of NCC in the kidneys may be critical to help to 557 elucidate the molecular events underlying the pathogenesis of essential hypertension. 558 
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